SL Science

🧠 Today is World Brain Day 2026 — "Brain Health: Access for All." The World Federation of Neurology reminds us that over 3.4 billion people globally live with neurological conditions, yet access to effective treatment remains deeply unequal. Glioblastoma (GBM) — a malignant brain tumor with a median survival of approximately 15 months — sits at the sharpest edge of this inequity, with limited response to surgery, radiation, and chemotherapy. This is exactly why what happened at WCP 2026 in Melbourne last week matters. SL Science Holding Limited (NASDAQ: SLBT), in collaboration with Taipei Medical University, JY BioMed, and HeXun Biosciences, presented preclinical findings on our gamma delta (γδ) T-cell platform — a next-generation immune cell therapy designed to address the limitations of conventional solid tumor treatment. Headline results: ✅ Complete tumor eradication achieved by Day 26 at the highest dose tested (8:1 effector-to-target ratio) ✅ Dose-dependent tumor suppression confirmed with repeated direct intracranial dosing ✅ No major safety concerns or adverse effects observed "We were thrilled to present these findings on a global stage. By working closely with leading academic institutions, we are translating complex biology into tangible hope for patients facing high unmet medical needs." — William Wang, Chairman & CEO, SL Science On World Brain Day, we are reminded that access to better science is itself a form of access to better health. We remain committed to delivering that science — for the patients who need it most. #WorldBrainDay2026 #BrainHealthAccessForAll #SLBT #Glioblastoma #GammaDeltaTCell #WCP2026 #CellTherapy #Immunotherapy #Oncology

We're proud to share that our CTO, Dr. Ethan Shen, attended WCP2026 Melbourne alongside JY BioMed's CMO, Dr. Bo-Xiang Zhang — as GDT platform preclinical findings took the world stage, with tumor signal dropping to undetectable levels in the highest-dose glioblastoma model. A meaningful milestone for the GDT platform's global journey. #SLScience #SLBT #Nasdaq #GDT #CellTherapy #BrainCancer #GBM #WCP2026 #Melbourne #Biotech

SL Science advances on two fronts in GDT brain cancer development. SL Science Holding Limited (Nasdaq: SLBT) has submitted an Orphan Drug Designation (ODD) request to the U.S. FDA for Vdelta2+ Gamma Delta T Cells for the treatment of glioblastoma multiforme (GBM). The FDA's Office of Orphan Products Development (OOPD) has formally acknowledged receipt of the request. Designation Details: 🔸Product: Vdelta2+ Gamma Delta T Cells 🔸Disease / Condition: Glioblastoma Multiforme (GBM) 🔸Designation Request Number: DRU-2026-11528 🔸Date of Receipt: March 30, 2026 Simultaneously, JY BioMed — licensor of SL Science's GDT cell therapy technology — will present at the 20th World Congress of Basic and Clinical Pharmacology (WCP2026) in Melbourne, Australia (July 12–17, 2026), with the presentation titled: "Intracranial γδ T Cell Therapy Eliminates Glioblastoma in Preclinical Models." Glioblastoma multiforme is among the most aggressive primary brain cancers, with a median survival of around 15 months and severely limited treatment options. ODD formally recognizes this unmet medical need and may provide regulatory support to accelerate the path to patients. SL Science's GDT platform offers a distinct immunological mechanism — MHC-independent tumor recognition that directly targets cancer cells, overcoming tumor heterogeneity and immune evasion in solid tumors. Two regulatory and scientific milestones. One platform. One mission. 📄 Read the full press release: https://lnkd.in/gTmqxkd5 #SLScience #SLBT #Nasdaq #GDT #CellTherapy #OrphanDrug #BrainCancer #Glioblastoma #GBM #WCP2026 #Melbourne #FDA #Immunooncology #Biotech

The scientific foundation behind SL Science's GDT platform continues to gain international validation. SL Science Holding Limited (Nasdaq: SLBT) licenses its proprietary Gamma Delta T (GDT) cell therapy technology from JY BioMed Co., Ltd., the IP holder of the GDT platform. Earlier this year, JY BioMed — in collaboration with Taipei Medical University — published a key preclinical study in the peer-reviewed journal Immunobiology: 📄 Title: Unmodified γδ T cells exhibit potent antitumor activity in hepatocellular carcinoma and are enhanced by PD-L1 blockade Key findings: 🔹Unmodified γδ T cells demonstrated strong, dose-dependent cytotoxic activity against hepatocellular carcinoma (HCC) in both in vitro and in vivo models 🔹Combining GDT cells with PD-L1 checkpoint blockade significantly enhanced antitumor efficacy, supporting future combination therapy strategies 🔹No significant systemic toxicity was observed in animal models, with potential for off-the-shelf allogeneic cell therapy development The MHC-independent tumor recognition capability of γδ T cells — enabling direct cancer cell targeting without the limitations of tumor heterogeneity — is the same scientific principle underlying SL Science's focus on pancreatic and brain cancers, two of the most challenging solid tumor indications in oncology. One platform. Multiple fronts. A growing body of peer-reviewed evidence. SL Science Holding Limited (Nasdaq: SLBT) #SLScience #SLBT #Nasdaq #GDT #CellTherapy #Immunooncology #HCC #PancreaticCancer #BrainCancer #Biotech #Immunobiology

At SL Science Holding Limited (Nasdaq: SLBT), we believe the future of oncology lies within the immune system itself. Our Gamma Delta T (GDT) cell therapy platform is designed to do what conventional treatments struggle with — precisely targeting solid tumors like pancreatic and brain cancers, triggering destruction from within, while leaving healthy tissue unharmed. This isn't about introducing a foreign substance. It's about empowering your own immune cells to work smarter. We're advancing next-generation, off-the-shelf cellular therapies to make this accessible — for patients who are still waiting. #SLScience #SLBT #Nasdaq #GDT #CellTherapy #Immunooncology #SolidTumors #PancreaticCancer #BrainCancer

We're excited to share SL Science's official company introduction video, now live on YouTube. SL Science Holding Limited (Nasdaq: SLBT) is advancing next-generation Gamma Delta T (GDT) cell therapy for solid tumors — with a focus on pancreatic and brain cancers, two of the most challenging indications in oncology. In this video, you'll learn about: - Our GDT cell therapy platform and its mechanism of action - Our mission to make cell therapy more accessible - How our Nasdaq listing strengthens our path toward global clinical development 📺 Watch now: https://pse.is/99ave5 #SLScience #SLBT #Nasdaq #CellTherapy #GammaDeltaT #Biotech #Oncology #SolidTumors

SL Science Holding Limited (Nasdaq: SLBT) today released its Full Year 2025 Financial Results, marking a pivotal year of strategic transformation. Key highlights: ✅ R&D Investment: >94% of annual revenue (~US$2.1M) deployed into cell therapy programs ✅ GDT Platform: Tech-transfer to FDA-compliant CDMO complete; IND targeted Q3 2027 ✅ CD-19 Armed-T: Addressing FDA feedback; Pre-IND meeting & IND targeted Q1 2027 ✅ Capital: Nasdaq listing + US$7.8M PIPE financing completed June 2026 Note: Year-end cash of US$1.26M does not reflect the June 2026 PIPE, which significantly strengthened our liquidity. Capital Update: Nasdaq listing (SLBT) and US$7.8M PIPE financing completed in June 2026, significantly strengthening liquidity. Our vision: Establish SL Science as one of the leading allogeneic Gamma Delta T cell platforms in Asia with global commercialization potential. Where treatment begins, beyond limits. Read the full press release 👇 https://lnkd.in/dhbBBeb8 #SLBT #SLScience #CellTherapy #GammaDeltaT #AllogeneicTherapy #Oncology #Biotech #Nasdaq #LifeSciences #ClinicalStage #ImmunoOncology

📢 $SLBT is officially listed on the Nasdaq Global Market — trading starts today. Formerly known as SL BIO Ltd., SL Science Holding Limited (Nasdaq: SLBT) marks a pivotal step — not just as a capital markets milestone, but as a declaration of where scalable allogeneic cell therapy is headed next. SL Science's off-the-shelf cellular therapy platform addresses standardization, manufacturing capacity, and cost barriers — transforming cell therapy from a bespoke procedure into a scalable, reproducible, platform-based model. We believe the most transformative force in precision medicine is a system that scales — not a breakthrough that can't. 🌐 https://lnkd.in/eg56ruJT 📩 ir@slbtgroup.com #SLBT #SLScience #Nasdaq #Biotech #CellTherapy #OncologyInnovation